The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 05, 2010
Filed:
Sep. 14, 2006
Anita Diu-hercend, Charenton le Pont, FR;
Julian Golec, Ashbury, GB;
Thierry Hercend, Charenton le Pont, FR;
Ronald Knegtel, Abingdon Oxfordshire, GB;
Paul Lang, Viuz-en-Sallaz, FR;
Andrew Miller, Upton, GB;
Karen Miller, West Ilsley, GB;
Michael Mortimore, Burford Oxforshire, GB;
Peter Weber, Abingdon Oxfordshire, GB;
Anita Diu-Hercend, Charenton le Pont, FR;
Julian Golec, Ashbury, GB;
Thierry Hercend, Charenton le Pont, FR;
Ronald Knegtel, Abingdon Oxfordshire, GB;
Paul Lang, Viuz-en-Sallaz, FR;
Andrew Miller, Upton, GB;
Karen Miller, West Ilsley, GB;
Michael Mortimore, Burford Oxforshire, GB;
Peter Weber, Abingdon Oxfordshire, GB;
Vertex Pharmaceuticals Incorporated, Cambridge, MA (US);
Abstract
The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1-('IL-1'), apoptosis-, interferon-γ inducing factor-(IGIF), interferon-γ-('IFN-γ'), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention. This invention also relates to methods for inhibiting caspase and TNF-alpha activity and decreasing IGIF production and IFN-γ production and methods for treating caspase-, interleukin-1, apoptosis-, and interferon-γ-, and TNF-alpha mediated diseases using the compounds and compositions of this invention.